304.00

0.72% -2.6619

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Why ALNY Down? Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $304.00, with a volume of 78,277. It is down -0.72% in the last 24 hours and down -8.53% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Previous Close:

$306.66

Open:

$303.42

24h Volume:

78,277

Relative Volume:

0.05

Market Cap:

$40.28B

Revenue:

$3.71B

Net Income/Loss:

$313.75M

P/E Ratio:

134.69

EPS:

2.2571

Net Cash Flow:

$465.38M

1W Performance:

-4.98%

1M Performance:

-8.53%

6M Performance:

-33.58%

1Y Performance:

+4.74%

1-Day Range:

$302.12

$305.97

1-Week Range:

$302.12

$323.23

52-Week Range:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1114)

Industry

Biotechnology (621)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,500

Twitter

@alnylam

Next Earnings Date

2026-02-12

Latest SEC Filings

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALNY Alnylam Pharmaceuticals Inc	303.70	40.67B	3.71B	313.75M	465.38M	2.2571
VRTX Vertex Pharmaceuticals Inc	443.46	114.63B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	730.69	77.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	668.61	42.32B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	138.69	31.04B	606.42M	-1.28B	-997.58M	-6.403

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Downgrade	Jefferies	Buy → Hold
Jan-28-26	Resumed	Barclays	Overweight
Jan-07-26	Resumed	Oppenheimer	Outperform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Mar-31-25	Initiated	Redburn Atlantic	Buy
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

09:00 AM

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis - Business Wire

09:00 AM

07:30 AM

Alnylam backs AI screening and a 10-site effort for missed heart disease - Stock Titan

07:30 AM

04:42 AM

Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

04:42 AM

Mar 22, 2026

Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 22, 2026

Mar 21, 2026

Chart Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividend2026 EndofYear Setup & Weekly High Return Forecasts - baoquankhu1.vn

Mar 21, 2026

Growth Review: What analysts say about Alnylam Pharmaceuticals Inc stockQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn

Mar 21, 2026

Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN

Mar 21, 2026

Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge - MSN

Mar 21, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to "Hold" - MarketBeat

Mar 21, 2026

Mar 20, 2026

Polar Asset Management Partners Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 20, 2026

Alnylam and Tekmira Restructure Relationship and Settle All Litigation - Yahoo

Mar 20, 2026

Mar 19, 2026

Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY - Sahm

Mar 19, 2026

Can Alnylam's Pipeline Medications Drive Sustainable Growth in the Future? - Bitget

Mar 19, 2026

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail

Mar 19, 2026

Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice

Mar 19, 2026

Groupama Asset Managment Purchases 2,483,697 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 19, 2026

CIBC Private Wealth Group LLC Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 19, 2026

1ALNY.MI Income Statement | ALNYLAM PHARMACEUTICALS INC (BIT:1ALNY) - ChartMill

Mar 19, 2026

Mar 18, 2026

Canaccord Genuity maintains buy rating on Alnylam Pharmaceuticals, Inc. (ALNY) stock - MSN

Mar 18, 2026

Mar 17, 2026

Alnylam Pharmaceuticals Q2 2025 Earnings Preview - MSN

Mar 17, 2026

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga

Mar 17, 2026

The $3B Biotech With Two Shots On Goal - Benzinga

Mar 17, 2026

Linden Advisors LP Makes New $6.55 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 12.8% in February - MarketBeat

Mar 17, 2026

Brevan Howard Capital Management LP Buys Shares of 6,170 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

Jefferies downgrades Alnylam Pharmaceuticals (ALNY) - MSN

Mar 17, 2026

California Public Employees Retirement System Buys 18,060 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

Bamco Inc. NY Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

(ALNY) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 17, 2026

A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Tenaya Cardiovascular Partnership - simplywall.st

Mar 17, 2026

Mar 16, 2026

JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN

Mar 16, 2026

ALNY Downgraded by Jefferies with Price Target Significantly Low - GuruFocus

Mar 16, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Hold Rating from Jefferies Financial Group - MarketBeat

Mar 16, 2026

Jain Global LLC Purchases 61,316 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 16, 2026

Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More - Yahoo Finance

Mar 16, 2026

Patisiran Comprehensive Forecast on the Accelerating Market - openPR.com

Mar 16, 2026

Mar 15, 2026

6,888 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Capula Management Ltd - MarketBeat

Mar 15, 2026